Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Biogen BOD awards CEO US$17.69 million despite drug failure

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 04, 2022 1:37pm

199 Views

Post# 34655628

RE:RE:Biogen BOD awards CEO US$17.69 million despite drug failure

Nearly 40% of Biogen investors said they want a CEO with a track record of successful business development, either through in-licensing deals or acquisitions, an RBC Capital Markets survey shows. By comparison, R&D expertise and cost-cutting experience were less valued.

https://www.fiercepharma.com/pharma/new-biogen-ceos-most-prized-expertise-dealmaking-experience-say-investors

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals